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Epilepsy Benchmarks
Epilepsy Resources and Updates
The Epilepsy Benchmark goals in Area III focus on making 
progress in understanding and controlling seizures and related 
conditions as well as on developing biomarkers and new 
therapies that will reduce seizures and improve outcomes for 
individuals with epilepsy. Area III emphasizes a need to better 
understand the ways in which seizures start, propagate, and 
terminate and whether those network processes are common 
or unique in different forms of epilepsy. The application of that 
knowledge to improved seizure prediction and detection will 
also play a role in improving patient outcomes. Animal models 
of treatment-resistant epilepsy that are aligned with etiolo-
gies and clinical features of human epilepsies are especially 
encouraged as necessary tools to understand mechanisms 
and test potential therapies. Antiseizure therapies that target 
(either alone or in combination) novel or multiple seizure 
mechanisms are prioritized in this section of the Benchmarks. 
Area III goals also highlight validation of biomarkers of treat-
ment response and safety risk, effective self-management, and 
patient-centered outcome measures as important areas of 
emphasis for the next five to ten years.
Key Advances in Area III
Developing and Refining Animal Models
Animal models are needed to test interventions targeted 
to various features of epilepsy, such as delaying the latency 
between initial insult and onset of spontaneous seizures, 
preventing the progression of epilepsy severity over time, 
converting pharmacoresistant to anticonvulsant-responsive 
seizures, and alleviating behavioral comorbidities. Progress 
has been made to address some of these aspects of disease 
modification and to identify etiologically relevant epilepsy 
animal models. One etiologically relevant animal model of 
cerebral viral infection is that produced by inoculation of mice 
with Theiler murine encephalomyelitis virus, which produces a 
strong neuroinflammatory reaction coupled with seizures and 
the development of long-term cognitive deficits (1). A similar 
model of cerebral malaria produces epilepsy that appears 
dependent on an intact complement pathway (2).
Posttraumatic epilepsy is a leading cause of epilepsy in 
young adults. Much effort has been devoted to develop-
ing etiologic animal models that lend themselves to drug 
screening and can be used to understand mechanisms of 
epileptogenesis in this condition. A recent study (3) reported 
the parametric optimization of a rat fluid percussion model 
that results in focal, nonconvulsive, brief seizures. In this model 
young (1 month old) male Sprague Dawley rats are subjected 
to an abrupt percussive injury to the parietal cortex. Within 
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a week in this model, most animals develop high-amplitude 
propagating spike trains in the theta frequency range that 
last from 1 second to about 5 minutes and are time-linked 
to stereotyped behaviors. Although similar EEG activity and 
behaviors are seen in clinically normal older male Sprague 
Dawley rats (4, 5), such activity is reported to not occur in 
sham-operated young rats (3, 6). Eastman et al. (3) systemati-
cally evaluated the effects of number and placement of EEG 
electrodes, seizure definition, and group size to determine the 
minimum recording time needed to detect a 50% change in 
seizure frequency with 80% statistical power. Surprisingly, with 
optimum electrode montage 24-hour recordings from six rats 
are sufficient, a much briefer time and a smaller number of 
animals than would generally be required to detect a signifi-
cant effect based on a statistical power analysis. This model 
was used to demonstrate that transient cooling of the injured 
cortex (2° for 5.5 weeks) was neuroprotective and prevented 
the development of seizure-like events (6). Whether the briefer 
bursts represent actual seizures remains controversial al-
though the careful parametric analysis (3) illuminates the way 
to more efficient preclinical trials in this and other models.
A zebrafish model of Dravet syndrome (Scn1a homozygous 
mutant) was recently introduced (7) and used to screen a small 
library of marketed compounds in an effort to identify new 
classes of anticonvulsants for this genetic epilepsy (8). Testing 
a known drug that has proven effective in Dravet syndrome 
(fenfluramine) indicated activity, providing validation. Another 
antiseizure drug (dimethadione) was identified in the screen 
but has not yet been evaluated for clinical activity in Dravet 
syndrome. A limitation of the model is that concentrations at 
relevant targets are not know (concentrations of fenfluramine 
500 to 2,500-fold, those that are achieved with clinically rel-
evant doses, were used, but access may be limited). Moreover, 
many drugs safe for humans cause mortality in zebrafish, and 
it can be difficult to separate antiseizure activity from neu-
rological toxicity. Zebrafish could be produced with patient-
specific mutations to screen for agents that might provide a 
personalized treatment approach for an individual patient.
Identifying Biomarkers
Biomarkers of medical treatment response remain elusive, 
but novel techniques may improve surgical localization and 
postsurgical deficit prediction. A pilot study using 7-Tesla MRI 
glutamate chemical exchange saturation transfer (GluCEST) (9) 
correctly lateralized the seizure focus in 4 patients with nonle-
sional temporal lobe epilepsy based on conventional 3-Tesla 
MRI. The magnetic resonance spectra, available for a subset of 
4 patients and 11 control subjects, corroborated the GluCEST 
findings. Hippocampal volumes were not significantly different 
between hemispheres. GluCEST allowed high-resolution func-
tional imaging of brain glutamate and has potential to identify 
the epileptic focus in patients previously deemed nonlesional.
Development of novel functional MRI (fMRI) memory tasks 
may improve identification of postsurgical memory outcome. 
Over the past 15 years, many attempts have been made to 
identify patients at risk for developing verbal memory deficits 
after a standard anterior temporal lobectomy (anterior temporal 
neocortex and mesial temporal structures). These efforts have 
been only partially successful. Recently, asymmetry of fMRI 
activation related to an in-scanner verbal memory encoding 
task with post-fMRI recall probe predicted memory outcomes 
following anterior temporal lobectomy (10). These efforts show 
promise for improved fMRI signatures that will non-invasively 
identify patients at risk for postsurgical memory deficits.
High-mobility group box 1 (HMGB1) is a nonhistone 
chromatin chaperone protein that, upon injury or initiation 
of an inflammatory reaction, is translocated from the nucleus 
to the cytoplasm and eventually secreted, finding its way into 
the bloodstream. Oxidative stress converts cysteines 23 and 25 
from the reduced -SH to the oxidized S-S form, which activates 
the NFκB and other inflammatory pathways (11). HMGB1 has 
received attention as a potential prognostic biomarker for 
cancer (12), stroke (13, ClinicalTrials.gov ID NCT01705353), and 
other conditions involving tissue injury coupled with sterile 
inflammation. HMGB1 is also translocated to the cytoplasm in 
astrocytes of mice and people with epilepsy (14), and it appears 
in the serum of rats 12 hours after status epilepticus, and is also 
found in the serum of patients with epilepsy (15, 16). HMGB1 
thus appears promising as a serum biomarker of inflammation-
associated brain injury during the process of epileptogenesis.
Understanding Seizure Dynamics
Recent advances in understanding seizure propagation could 
improve surgical outcomes for patients. A study of the spa-
tiotemporal dynamics of seizure propagation on intracranial 
EEG (17) reported better surgical outcomes in patients with a 
consistent and organized pattern of seizure propagation from 
seizure to seizure than in patients without consistent spatial 
organization of activity during recruitment. Seizures can be 
recorded in humans with high-resolution microelectrodes to 
distinguish different seizure types at multiple scales (18). Such 
studies require development of novel analytic tools to process 
the large amounts of data. In one study, high-bandwidth 
recordings through microelectrode arrays in presurgical 
patients revealed a rather compact seizure-generating ictal 
core surrounded by a larger ictal penumbra that was some-
times recruited into the seizure wavefront (19). An improved 
understanding of how the seizure-initiating core recruits brain 
regions that generate large amplitude voltage fluctuations 
provides novel information that may improve surgical treat-
ment of epilepsy and highlights the slow spread of massive 
local activity across a large extent of cortex during seizure.
An alternative approach is to quantify the basic dynamics 
of seizures. Recent work using bifurcation analysis (20) identi-
fied several inherent dynamic properties of seizure onset and 
offset that are conserved across multiple species and brain 
regions. In particular, within a simple computational model the 
onset and offset of ictal-like discharges could be described as 
mathematical events, a saddle-node and homoclinic bifurca-
tion, respectively. These bifurcations require a baseline shift 
at onset, consistent with the direct-current voltage change 
seen in wide bandwidth recording and logarithmic scaling of 
interspike intervals at offset. These predictions were confirmed 
in humans and zebrafish.
Improved Seizure Detection, Prediction, and Termination
Advances in implantable devices for epilepsy saw several 
milestones in the past years. The feasibility of seizure predic-
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tion was demonstrated in humans in a landmark study by 
Australian investigators. In this study, a novel implantable 
device sent intracranial EEG measurements via telemetry to a 
personal handheld computer capable of real-time analytics. 
The computer provided seizure forecasts, i.e., estimates of low 
and high seizure likelihood that were found to be significantly 
better than chance (21). Further work is ongoing to replicate 
findings based on non-invasive recording techniques of physi-
ological signals.
An effort to crowd-source solutions to the problems of 
seizure detection and prediction from intracranial EEG data 
took the form of a contest sponsored by the National Institutes 
of Health, American Epilepsy Society, and Epilepsy Founda-
tion of America. The contest was hosted on Kaggle.com and 
sparked interest from engineers all around the world. In just 
a few months, teams with no prior expertise in epilepsy were 
consistently achieving accuracy as high as 84% for classifica-
tion of interictal versus preictal data clips from humans and 
canines with focal epilepsy. A total of 504 teams participated 
in the two contests, one for detecting seizures and the other 
for predicting seizures using huge intracranial EEG data sets. 
The Seizure Detection Challenge was won by an Australian 
software engineer. The Seizure Prediction Challenge was a 
tight seven-way race, with first place awarded to a team of 
five engineers and scientists who decided to join forces as the 
contest progressed. The data and software are freely available 
to researchers worldwide by the National Institute of Neuro-
logical Disorders and Stroke, University of Pennsylvania, and 
Mayo Clinic (ieeg.org and msel.mayo.edu) (22).
Improve Antiseizure Therapies That Target Novel or Multiple 
Seizure Mechanisms
Therapeutic advances have been made during the past 
several years in medication, surgical, and stimulation-based 
approaches to controlling seizures, some with improved side-
effect profiles. However, all therapeutic interventions aimed at 
controlling seizures have side effects, and novel therapies may 
present other unforeseen adverse events that limit use and 
require additional research to address in an iterative manner.
Ezogabine, also known as retigabine, is a Kv7 potassium 
channel opener that was approved for adjunctive therapy for 
focal seizures in individuals with refractory seizures who are 18 
years and older. Efficacy for this first-in-class agent was demon-
strated in phase III clinical trials (23, 24). Safety issues associated 
with ezogabine include dizziness, somnolence, confusion, and 
fatigue, which are all common for CNS-acting drugs. However, 
use of ezogabine is also associated with increased risk of neuro-
psychiatric events (including confusion, hallucinations, and psy-
chosis), urinary retention, increased post-void residual volume, 
and blue discoloration of skin and eyes. The retinal and skin 
abnormalities may be permanent and thus resulted in labeling 
changes required by the U.S. Food and Drug Administration in 
2013 (25). For these reasons, despite the advance represented 
by its novel mechanism of action, ezogabine has a boxed warn-
ing and is generally not considered for use until seizures have 
failed to respond to several other antiseizure medications (26).
In January 2014, perampanel, a new antiseizure drug act-
ing in part as a noncompetitive AMPA receptor antagonist, was 
launched in the United States. Efficacy was demonstrated in 
studies of both focal-onset (27) and primary generalized tonic-
clonic (28) seizures although adverse events, including dizzi-
ness, somnolence, ataxia, fatigue, and neuropsychiatric events 
(including aggression and homicidal ideation), were flagged as 
side effects in some patients (see the Area IV report and [29]). 
Three phase III studies published in 2015 (30) documented the 
efficacy of perampanel in patients with drug-resistance partial 
seizures after the conversion from double-blind placebo to 
open-label perampanel.
Brivaracetam, the 4-n-propyl analog (levetiracetam) was 
approved by the U.S. Food and Drug Administration in February 
2016 as adjunctive therapy for the treatment of partial-onset 
seizures in patients with epilepsy aged 16 years and older. Bri-
varacetam was discovered in a medicinal chemistry campaign 
seeking to enhance the binding affinity to SV2A, the molecular 
target of levetiracetam, and is one of the few rationally designed 
antiseizure drugs (31). The most common side effects reported 
in clinical trials included drowsiness, dizziness, fatigue, nausea, 
and vomiting (32). The extent to which brivaracetam will pro-
vide advantages to levetiracetam remains to be determined.
Several novel invasive approaches have been introduced 
to patients with epilepsy in the past several years. Deep brain 
stimulation for epilepsy continues to show promise. Two recent 
studies have demonstrated the long-term efficacy of thera-
peutic brain stimulation using either duty cycle stimulation 
of the anterior nucleus of thalamus (33), or focal stimulation 
targeted to the seizure focus that is triggered by certain EEG 
patterns (34). Both therapeutic stimulation approaches showed 
continued improvement in efficacy with time, demonstrating 
that brain stimulation is a durable therapy for focal epilepsy. 
Responsive stimulation has been shown to reduce seizure fre-
quency and improve quality of life in patients with treatment-
refractory partial-onset epileptic seizures (34–36). Moreover, 
at 2 years, there was a small but significant improvement in 
naming in patients with neocortical seizure onset, as well as im-
provement in learning in patients with seizure onset from the 
mesial temporal structures (37). The Stimulation of the Anterior 
Nucleus of the Thalamus for Epilepsy (SANTE) trial has shown 
efficacy in reducing seizure burden in patients with medically 
intractable epilepsy, and gains were reported in quality of 
life along with an improvement in several neuropsychologi-
cal measures (33). The infrequent but most common serious 
adverse event in the responsive neurostimulation and SANTE 
trials was infection at the implant site. Pilot studies point to 
stereotactic laser ablation being efficacious, and it seems to be 
associated with fewer cognitive consequences than traditional 
open resection approaches (38), arguing that many of the 
cognitive deficits associated with resective surgery reflect col-
lateral surgically imposed damage to the tissue adjacent to the 
ictal focus (See also the Area IV report). While the initial data on 
quality of life and adverse events of these alternative surgical 
interventions is encouraging, ongoing systematic and stan-
dardized evaluation of large patient cohorts will be important 
for more definite assessment of their utility in clinical practice.
Improve Self-Management
Epilepsy self-management refers to a number of behaviors and 
actions that a person with epilepsy can employ to promote 
seizure control and enhance quality of life. Collection of infor-
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mation has also driven by advances in wearable devices and 
portable healthcare technology as well as phone and device 
applications. Various programs of self-management have 
been developed, and recent Cochrane reviews of the available 
self-management tools and intervention programs through 
2013 were evaluated for children and for adults. In both cases, 
the quality of the evidence in the analysis was considered 
relatively low. Recommendations for additional research in 
this area included the use of randomized controlled clinical 
trials (rather than observational studies), sufficient detail about 
the intervention, and sufficient numbers of interventionalists 
(if used) so that individual-specific variables such as level of 
training or interaction style do not confound results (39, 40). 
A bright spot in this area is the Centers for Disease Control 
and Prevention’s Managing Epilepsy Well Network, which is 
advancing the field of self-management research and tools for 
epilepsy (41). In 2015, results of a randomized controlled trial 
of a self-management program for adults showed improved 
Epilepsy Self-Management Scale and quality-of-life scores in 
the intervention group that persisted for up to 6 months after 
the intervention (42). Further, investigators working with the 
Managing Epilepsy Well Network have published an informat-
ics-based approach using an epilepsy ontology to maximize 
the secondary use of clinical data; this proof of concept could 
be more broadly applicable to data sharing across many other 
areas of epilepsy research as well (43).
Looking Forward: Challenges and Opportunities
New therapies that have fewer, or more tolerable, adverse con-
sequences than current treatment approaches are under devel-
opment in several sectors. For example, preliminary experimen-
tal work suggests that focal cooling of perilesional neocortical 
seizure foci may reduce seizure activity (6, 44). Pilot human 
studies also suggest that systemic therapeutic hypothermia may 
represent an effective means toward control of acute seizures 
or status epilepticus (45, 46). This is a promising novel approach 
in the management of acute seizures. Seizure detection using 
noninvasive wearable sensors, smart watches, and markers of 
multiple physiological signals, including ictal tachycardia, is an 
area of active clinical research and development. In addition, re-
search to optimize existing antiseizure medications to eliminate 
problematic side effects is also underway, tentatively using com-
parative effectiveness and “big data” approaches. In some cases, 
a better understanding of the fundamental neurobiology that 
generates neuropsychiatric symptoms such as hallucinations, 
suicidal ideation, aggression, or hostility will be necessary, as it is 
possible that the same mechanism of action that suppresses sei-
zures is also involved in generating neuropsychiatric symptoms. 
Likewise, comorbid pharmacotherapeutic effects on sleep and 
vigilance may need to be approached more comprehensively. 
The reciprocal interactions between sleep/circadian abnor-
malities and seizures need to be elucidated and could suggest 
opportunities for chronotherapy and individualized epilepsy 
management strategies to improve quality of life and seizure 
control. Off-target effects could also contribute to problematic 
side effects, and these effects could be amenable to optimiza-
tion through medicinal chemistry. Activities are also underway 
to increase the overall value of preclinical animal model testing 
in drug development for epilepsy (47).
New drug targets have been identified that will, if ultimately 
shown to be effective in clinical trials, expand the repertoire of 
anticonvulsant mechanisms of action (48). Metabolic control of 
excitability is an area of growing interest, given the long history 
of success with the ketogenic diet in children, and more recently 
with adults, with epilepsy refractory to other medications. Sada 
et al. (49) demonstrated that inhibition of lactate dehydro-
genase (LDH) suppresses seizures in both acute and chronic 
epilepsy models. The investigators then assessed whether exist-
ing antiseizure drugs had LDH-inhibiting properties, and found 
that stiripentol, a GABAergic agent, is also a potent inhibitor of 
LDH, suggesting metabolic control as an additional mechanism 
of action for this drug and further supporting the rationale for 
new drug development on metabolic targets. Mechanistic/
mammalian target of rapamycin (mTOR) pathway inhibitors are 
also in development as potential antiseizure targets in tuberous 
sclerosis complex (50), and they may also have potential for con-
trolling seizures associated with focal cortical dysplasia due to 
brain somatic mutations with a direct mechanistic link to mTOR 
overactivation (51–53). It remains to be seen whether mTOR-
based drugs may be useful in acquired epilepsies as well. 
An initial Phase 3 trial of cannabidiol as adjunctive treat-
ment of convulsive seizures in Dravet syndrome achieved a 
highly significant positive outcome. This is the first step in fill-
ing the void of Class I evidence with cannabiadiol for epilepsy. 
A second pivotal trial of cannabidiol in Dravet syndrome is in 
progress, as are two Phase 3 trials in Lennox-Gastaut syn-
drome, and a Phase 3 trial in tuberous sclerosis complex. The 
basic science underpinning the scientific rationale for using 
cannabinoids in epilepsy has also been growing in recent 
years. Although cannabidiol has low affinity for CB1 and CB2 
cannabinoid receptors, it may indirectly affect endogenous 
cannabinoid mechanisms or it could exert its therapeutic 
activity on non-cannabinoid-related targets. Endogenous are 
one of the body’s mechanisms to regulate excitability through 
retrograde inhibition of neurotransmitter release, and possibly 
through other mechanisms as well. Cannabinoids modulate 
GABAergic interneurons and interneuron-generated network 
rhythms (54). Understanding the principles that govern the 
control and plasticity of the endocannabinoid system in 
response to recurring spontaneous seizures will likely be criti-
cal to understanding the potential and limits of cannabinoid-
based therapies for various forms of epilepsy.
Modulation of homeostatic processes is an alternative 
strategy for suppressing seizure-promoting events. Adenosine 
acts as an endogenous antiseizure agent (reviewed by [55]), 
and recent work demonstrating a rise in adenosine levels just 
prior to seizure termination in animal models and human 
epilepsy patients (56) further supports the adenosine system 
as an important homeostatic target for new antiseizure drug 
development. Adenosine may have a role as an anti-epilepto-
genic agent as well (See the Area II report).
Finally, Area III goals also highlight validation of biomark-
ers of treatment response and safety risk as well as patient-
centered outcome measures as important areas of emphasis 
for the next five to ten years. Although less progress has been 
apparent in these areas to date, they remain, nonetheless, 
important areas in which advances can help to reduce the 
burdens of epilepsy on individuals and families.
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